Utility of cerebrospinal fluid drug concentration as a surrogate for unbound brain concentration in nonhuman primates.
Yoko Nagaya, Yoshitane Nozaki, Kazumasa Kobayashi, Osamu Takenaka, Yosuke Nakatani, Kazutomi Kusano, Tsutomu Yoshimura, Hiroyuki Kusuhara
Index: Drug Metab. Pharmacokinet. 29(5) , 419-26, (2014)
Full Text: HTML
Abstract
In central nervous system drug discovery, cerebrospinal fluid (CSF) drug concentration (C(CSF)) has been widely used as a surrogate for unbound brain concentrations (C(u,brain)). However, previous rodent studies demonstrated that when drugs undergo active efflux by transporters, such as P-glycoprotein (P-gp), at the blood-brain barrier, the C(CSF) overestimates the corresponding C(u,brain). To investigate the utility of C(CSF) as a surrogate for interstitial fluid (ISF) concentration (C(ISF)) in nonhuman primates, this study simultaneously determined the C(CSF) and C(ISF) of 12 compounds, including P-gp substrates, under steady-state conditions in cynomolgus monkeys using intracerebral microdialysis coupled with cisternal CSF sampling. Unbound plasma concentrations of non- or weak P-gp substrates were within 2.2-fold of the C(ISF) or C(CSF), whereas typical P-gp substrates (risperidone, verapamil, desloratadine, and quinidine) showed ISF-to-plasma unbound (K(p,uu,ISF)) and CSF-to-plasma unbound concentration ratios (K(p,uu,CSF)) that were appreciably lower than unity. Although the K(p,uu,CSF) of quinidine, verapamil, and desloratadine showed a trend of overestimating the K(p,uu,ISF), K(p,uu,CSF) showed a good agreement with K(p,uu,ISF) within 3-fold variations for all compounds examined. C(u,brain) of some basic compounds, as determined using brain homogenates, overestimated the C(ISF) and C(CSF). Therefore, C(CSF) could be used as a surrogate for C(ISF) in nonhuman primates.
Related Compounds
Related Articles:
2005-05-05
[J. Med. Chem. 48 , 3269-79, (2005)]
2013-01-01
[Undersea Hyperb. Med. 40(3) , 223-9, (2013)]
2012-12-07
[Neurosci. Lett. 531(2) , 160-5, (2012)]
Edaravone alleviates hypoxia-acidosis/reoxygenation-induced neuronal injury by activating ERK1/2
2013-05-24
[Neurosci. Lett. 543 , 72-7, (2013)]
2013-07-04
[Toxicol. Lett. 220(2) , 135-42, (2013)]